AbbVie Inc.'s patent infringement suit against Amgen Inc. over its proposed biosimilar to Humira (adalimumab) may provide the most complete picture yet of what "patent dance"-choreographed litigation could look like, but the complaint also contends that Amgen has not provided full information about its manufacturing process.
The suit, filed Aug. 4 in the U.S. District Court for the District of Delaware, claims Amgen's product...






